Volume Alert - VRX 136.16 Valeant Pharmaceuticals
Post# of 193
Posted On: 11/17/2014 11:27:37 AM
Volume Alert - VRX 136.16 Valeant Pharmaceuticals International $VRX Hit a high today of 136.50 Closing the day 10:30 at 136.16 +1.95 +1.45% With a day low of 132.73 and a total volume of 3,820,934.
VRX Recent Posts: http://investorshangout.com/Valeant-Pharmaceu...VRX-53038/
VRX Valeant Pharmaceuticals International Recent Headline News
Allergan's $66 Billion Actavis Deal is Still a Win for Bill Ackman
at The Street - 28 mins ago
Valeant says it can't justify $219 a share offer to shareholders.
ZTS: 43.91 (+0.77), AGN: 210.73 (+12.08), VRX: 135.65 (+1.44), ACT: 248.52 (+4.75)
Actavis to spend $66B on Allergan
By TOM MURPHY - AP - 40 mins ago
Actavis will pay $66 billion to buy fellow drugmaker Allergan in a deal that could finally end a months-long takeover push from Valeant Pharmaceuticals for the Botox maker.
DRTX: 23.94 (+0.19), AGN: 210.73 (+12.08), ACT: 248.52 (+4.75), VRX: 135.65 (+1.44), VRX.TO: 153.39 (+1.92)
Actavis Nabs Allergan For $66 Billion; Valeant Folds
at Investor's Business Daily - 1 hr 10 mins ago
One of the most widely rumored deals in pharma came to fruition Monday, as Actavis (ACT) agreed to acquire Allergan (AGN) for $66 billion in cash and stock. Allergan stock was up more than 7%, near 213, and Actavis stock up nearly 4%, near 253, in...
AGN: 210.73 (+12.08), VRX: 135.65 (+1.44), ACT: 248.45 (+4.68)
Time to move on: Valeant chief says $219 too rich
Seeking Alpha - at Seeking Alpha - 1 hr 13 mins ago
ACT: 248.45 (+4.68), VRX: 135.65 (+1.44)
Valeant Comments On Allergan Announcement
PR Newswire - 1 hr 58 mins ago
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock.
AGN: 210.77 (+12.12), ACT: 248.58 (+4.81), VRX: 135.65 (+1.44), VRX.TO: 153.39 (+1.92)
Stock Futures Set For Weak Open; Halliburton, Baker Hughes Merge
at Investor's Business Daily - 2 hrs 15 mins ago
Stock futures pointed modestly lower ahead of Monday's open as merger news stirred some of the most notable premarket stock moves. Dow futures sifted 27.7 points below fair market value. Nasdaq 100 futures were 9.1 points lower, and S&P 500 futures...
AGN: 210.77 (+12.12), HAS: 56.31 (+2.29), VRX: 135.65 (+1.44), ACT: 248.64 (+4.87), HAL: 50.68 (-4.40), DIS: 90.31 (-0.49), DWA: 22.28 (-3.74), BHI: 66.73 (+6.84)
Today's Market: Pharma And Tech Companies In Focus This Morning
Matthew Smith - at Seeking Alpha - 2 hrs 20 mins ago
AGN: 210.77 (+12.12), VRX: 135.65 (+1.44), ACT: 248.63 (+4.86), LNKD: 222.45 (-11.44), FB: 74.13 (-0.75), MSFT: 49.26 (-0.32), GOOG: 534.89 (-9.51)
Actavis Rumored to be Close to Acquiring Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 27 mins ago
As per market rumors, Actavis (ACT) is closing in on a deal to acquire Allergan (AGN) for over $65.5 billion.
DRTX: 23.94 (+0.19), ZTS: 43.91 (+0.77), AGN: 210.77 (+12.12), ACT: 248.58 (+4.81), VRX: 135.65 (+1.44)
Tracking Bill Ackman's Pershing Square Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 6:40AM CST
ZTS: 43.91 (+0.77), AGN: 210.77 (+12.12), HLF: 38.48 (-0.02), VRX: 135.65 (+1.44), ACT: 248.64 (+4.87), HHC: 142.97 (-0.71), PAH: 25.70 (+0.20), CP: 204.86 (+0.30), APD: 134.99 (+0.28), BKW: 32.05 (-0.24)
Wall Street Breakfast: Nikkei Dives As Japan Slips Into Recession
Wall Street Breakfast - Seeking Alpha - Mon Nov 17, 5:30AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Top long idea...
VRX: 135.65 (+1.44), ACT: 248.64 (+4.87), F: 15.35 (+0.21), FB: 74.13 (-0.75), PFE: 29.95 (-0.39), AGN: 210.79 (+12.14), YHOO: 51.35 (-0.40), PBR: 9.61 (-0.34), DFS: 64.86 (-0.12), DTSI: 32.78 (-0.25), SPY: 203.88 (-0.36), LNKD: 222.45 (-11.44), QQQ: 102.51 (-0.71), AME: 51.12 (-0.58), MRK: 59.71 (+0.64), AOL: 46.28 (+0.24), AZN: 72.14 (-0.71), GM: 32.16 (+0.37), CVEO: 10.53 (-0.11), DD: 70.50 (-0.30)
Actavis near deal to acquire Allergan for $210-220/share
Seeking Alpha - at Seeking Alpha - Sun Nov 16, 2:51PM CST
AGN: 210.79 (+12.14), ACT: 248.64 (+4.87), VRX: 135.65 (+1.44)
Tracking Lou Simpson's SQ Advisors Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Sun Nov 16, 10:03AM CST
BAM: 49.79 (+0.18), VRX: 135.65 (+1.44), LBTYK: 45.43 (-0.57), CCK: 48.22 (+0.68), WFC: 53.21 (-0.14), ORCL: 40.93 (+0.09), UPS: 106.40 (-0.43), MCO: 100.43 (-0.04), T: 35.84 (-0.06), USB: 43.75 (+0.02), TEL: 60.90 (-0.63), DTV: 87.22 (-0.33), BRK.B: 145.40 (-0.12), BRK.A: 218,035.00 (+12.00), SCHW: 28.57 (-0.30)
Tracking Glenn Greenberg's Brave Warrior Advisors Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Sat Nov 15, 10:45AM CST
KMI: 39.78 (+0.41), VRX: 135.65 (+1.44), HAL: 50.69 (-4.39), KMP: 97.14 (+0.89), BAC: 17.11 (-0.03), TDW: 37.56 (-0.23), VPRT: 67.60 (+0.80), ORCL: 40.93 (+0.09), PRI: 51.71 (-0.34), EPB: 41.87 (+0.42), ESRX: 78.35 (+0.48), EQIX: 221.58 (-0.51), JPM: 60.28 (unch), KMR: 98.09 (+1.13), MSFT: 49.26 (-0.32), CMCSA: 54.12 (+0.02), SCHW: 28.57 (-0.30)
After Yesterday's Rally of 1.80% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Nov 14, 3:59PM CST
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $131.34 to a high of $134.64. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $133.84 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRX: 135.65 (+1.44)
Merck KGaA Q3 Earnings Rise Y/Y, 2014 View Upgraded - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 1:20PM CST
Merck KGaA (MKGAF) reported third-quarter 2014 earnings of $1.53 per American Depositary Receipt (ADR), up 0.2% from the year-ago quarter.
LCI: 47.36 (+0.48), VRX: 135.65 (+1.44), ADHD: 3.45 (-0.21)
Valeant Should Drop Allergan Bid And Go For Zoetis
Kanak Kanti De - at Seeking Alpha - Fri Nov 14, 7:30AM CST
ZTS: 43.91 (+0.77), AGN: 210.85 (+12.20), VRX: 135.65 (+1.44), ACT: 248.67 (+4.90)
Will Actavis Snatch Allergan, Valeant Settle for Zoetis? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:28PM CST
A report from Bloomberg stated that Actavis is in discussions to Allergan for a deal worth at least $60 billion.
ZTS: 43.91 (+0.77), AGN: 210.85 (+12.20), ACT: 248.67 (+4.90), VRX: 135.65 (+1.44)
Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey
CNW Group - Thu Nov 13, 4:00PM CST
Expansion of its U.S. headquarters solidifies commitment to grow jobs and support the local economy
VRX: 135.65 (+1.44), VRX.TO: 153.39 (+1.92)
VRX Recent Posts: http://investorshangout.com/Valeant-Pharmaceu...VRX-53038/
VRX Valeant Pharmaceuticals International Recent Headline News
Allergan's $66 Billion Actavis Deal is Still a Win for Bill Ackman
at The Street - 28 mins ago
Valeant says it can't justify $219 a share offer to shareholders.
ZTS: 43.91 (+0.77), AGN: 210.73 (+12.08), VRX: 135.65 (+1.44), ACT: 248.52 (+4.75)
Actavis to spend $66B on Allergan
By TOM MURPHY - AP - 40 mins ago
Actavis will pay $66 billion to buy fellow drugmaker Allergan in a deal that could finally end a months-long takeover push from Valeant Pharmaceuticals for the Botox maker.
DRTX: 23.94 (+0.19), AGN: 210.73 (+12.08), ACT: 248.52 (+4.75), VRX: 135.65 (+1.44), VRX.TO: 153.39 (+1.92)
Actavis Nabs Allergan For $66 Billion; Valeant Folds
at Investor's Business Daily - 1 hr 10 mins ago
One of the most widely rumored deals in pharma came to fruition Monday, as Actavis (ACT) agreed to acquire Allergan (AGN) for $66 billion in cash and stock. Allergan stock was up more than 7%, near 213, and Actavis stock up nearly 4%, near 253, in...
AGN: 210.73 (+12.08), VRX: 135.65 (+1.44), ACT: 248.45 (+4.68)
Time to move on: Valeant chief says $219 too rich
Seeking Alpha - at Seeking Alpha - 1 hr 13 mins ago
ACT: 248.45 (+4.68), VRX: 135.65 (+1.44)
Valeant Comments On Allergan Announcement
PR Newswire - 1 hr 58 mins ago
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock.
AGN: 210.77 (+12.12), ACT: 248.58 (+4.81), VRX: 135.65 (+1.44), VRX.TO: 153.39 (+1.92)
Stock Futures Set For Weak Open; Halliburton, Baker Hughes Merge
at Investor's Business Daily - 2 hrs 15 mins ago
Stock futures pointed modestly lower ahead of Monday's open as merger news stirred some of the most notable premarket stock moves. Dow futures sifted 27.7 points below fair market value. Nasdaq 100 futures were 9.1 points lower, and S&P 500 futures...
AGN: 210.77 (+12.12), HAS: 56.31 (+2.29), VRX: 135.65 (+1.44), ACT: 248.64 (+4.87), HAL: 50.68 (-4.40), DIS: 90.31 (-0.49), DWA: 22.28 (-3.74), BHI: 66.73 (+6.84)
Today's Market: Pharma And Tech Companies In Focus This Morning
Matthew Smith - at Seeking Alpha - 2 hrs 20 mins ago
AGN: 210.77 (+12.12), VRX: 135.65 (+1.44), ACT: 248.63 (+4.86), LNKD: 222.45 (-11.44), FB: 74.13 (-0.75), MSFT: 49.26 (-0.32), GOOG: 534.89 (-9.51)
Actavis Rumored to be Close to Acquiring Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 27 mins ago
As per market rumors, Actavis (ACT) is closing in on a deal to acquire Allergan (AGN) for over $65.5 billion.
DRTX: 23.94 (+0.19), ZTS: 43.91 (+0.77), AGN: 210.77 (+12.12), ACT: 248.58 (+4.81), VRX: 135.65 (+1.44)
Tracking Bill Ackman's Pershing Square Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 6:40AM CST
ZTS: 43.91 (+0.77), AGN: 210.77 (+12.12), HLF: 38.48 (-0.02), VRX: 135.65 (+1.44), ACT: 248.64 (+4.87), HHC: 142.97 (-0.71), PAH: 25.70 (+0.20), CP: 204.86 (+0.30), APD: 134.99 (+0.28), BKW: 32.05 (-0.24)
Wall Street Breakfast: Nikkei Dives As Japan Slips Into Recession
Wall Street Breakfast - Seeking Alpha - Mon Nov 17, 5:30AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Top long idea...
VRX: 135.65 (+1.44), ACT: 248.64 (+4.87), F: 15.35 (+0.21), FB: 74.13 (-0.75), PFE: 29.95 (-0.39), AGN: 210.79 (+12.14), YHOO: 51.35 (-0.40), PBR: 9.61 (-0.34), DFS: 64.86 (-0.12), DTSI: 32.78 (-0.25), SPY: 203.88 (-0.36), LNKD: 222.45 (-11.44), QQQ: 102.51 (-0.71), AME: 51.12 (-0.58), MRK: 59.71 (+0.64), AOL: 46.28 (+0.24), AZN: 72.14 (-0.71), GM: 32.16 (+0.37), CVEO: 10.53 (-0.11), DD: 70.50 (-0.30)
Actavis near deal to acquire Allergan for $210-220/share
Seeking Alpha - at Seeking Alpha - Sun Nov 16, 2:51PM CST
AGN: 210.79 (+12.14), ACT: 248.64 (+4.87), VRX: 135.65 (+1.44)
Tracking Lou Simpson's SQ Advisors Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Sun Nov 16, 10:03AM CST
BAM: 49.79 (+0.18), VRX: 135.65 (+1.44), LBTYK: 45.43 (-0.57), CCK: 48.22 (+0.68), WFC: 53.21 (-0.14), ORCL: 40.93 (+0.09), UPS: 106.40 (-0.43), MCO: 100.43 (-0.04), T: 35.84 (-0.06), USB: 43.75 (+0.02), TEL: 60.90 (-0.63), DTV: 87.22 (-0.33), BRK.B: 145.40 (-0.12), BRK.A: 218,035.00 (+12.00), SCHW: 28.57 (-0.30)
Tracking Glenn Greenberg's Brave Warrior Advisors Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Sat Nov 15, 10:45AM CST
KMI: 39.78 (+0.41), VRX: 135.65 (+1.44), HAL: 50.69 (-4.39), KMP: 97.14 (+0.89), BAC: 17.11 (-0.03), TDW: 37.56 (-0.23), VPRT: 67.60 (+0.80), ORCL: 40.93 (+0.09), PRI: 51.71 (-0.34), EPB: 41.87 (+0.42), ESRX: 78.35 (+0.48), EQIX: 221.58 (-0.51), JPM: 60.28 (unch), KMR: 98.09 (+1.13), MSFT: 49.26 (-0.32), CMCSA: 54.12 (+0.02), SCHW: 28.57 (-0.30)
After Yesterday's Rally of 1.80% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Nov 14, 3:59PM CST
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $131.34 to a high of $134.64. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $133.84 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRX: 135.65 (+1.44)
Merck KGaA Q3 Earnings Rise Y/Y, 2014 View Upgraded - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 1:20PM CST
Merck KGaA (MKGAF) reported third-quarter 2014 earnings of $1.53 per American Depositary Receipt (ADR), up 0.2% from the year-ago quarter.
LCI: 47.36 (+0.48), VRX: 135.65 (+1.44), ADHD: 3.45 (-0.21)
Valeant Should Drop Allergan Bid And Go For Zoetis
Kanak Kanti De - at Seeking Alpha - Fri Nov 14, 7:30AM CST
ZTS: 43.91 (+0.77), AGN: 210.85 (+12.20), VRX: 135.65 (+1.44), ACT: 248.67 (+4.90)
Will Actavis Snatch Allergan, Valeant Settle for Zoetis? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:28PM CST
A report from Bloomberg stated that Actavis is in discussions to Allergan for a deal worth at least $60 billion.
ZTS: 43.91 (+0.77), AGN: 210.85 (+12.20), ACT: 248.67 (+4.90), VRX: 135.65 (+1.44)
Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey
CNW Group - Thu Nov 13, 4:00PM CST
Expansion of its U.S. headquarters solidifies commitment to grow jobs and support the local economy
VRX: 135.65 (+1.44), VRX.TO: 153.39 (+1.92)
(0)
(0)